Diagnosis of Occult Asthma by Methacholine Bronchoprovocation Test

Finasteride, a type 2 5a-reductase inhibitor, was developed to treat androgenetic alopecia and benign prostatic hyperplasia. Clinical trials demonstrated its effectiveness in men, showing visible hair growth in up to 66% of those with mild to moderate alopecia and halting hair loss in 91% of patients. Long-term studies indicated that placebo patients experienced significant hair loss, while finasteride users maintained scalp coverage, even after withdrawal. This suggests finasteride's dual role in preventing further hair loss and promoting hair growth, making it a strong candidate for early treatment of androgenetic alopecia in men.